Phase 1 Allogeneic Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Phase 1Phase 2
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Acute Leukemia, High RiskMyelodysplastic Syndromes, High RiskHematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
Ciusss de L'Est de l'Île de Montréal7 enrolled1 locationNCT07301866
Recruiting
Phase 1Phase 2
Donor-Derived Viral Specific T-cells (VSTs)
Viral reactivationallogeneic stem cell transplantViral Infection
Children's Hospital Medical Center, Cincinnati750 enrolled3 locationsNCT02048332
Recruiting
Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
Hematopoietic and Lymphoid Cell NeoplasmAllogeneic Hematopoietic Stem Cell Transplant Recipient
City of Hope Medical Center53 enrolled1 locationNCT04177004
Recruiting
Phase 1
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Phase 1
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Autoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06733610
Completed
Phase 1
A Randomized, Single-Dose and Multiple Dose Dose-Ranging Safety and Pharmacokinetics Study of Tacrolimus Powder for Inhalation in Healthy Adult Subjects
Prophylactic therapy of organ rejection in patients receiving allogeneic lung transplants
TFF Pharmaceuticals Australia Pty Limited64 enrolled2 locationsACTRN12620000192987
Completed
Phase 1
Infusion of virus specific immune cells in patients at the first sign of virus infection after a blood or bone marrow transplant who have received less than 7 days of anti-viral treatment.
Cytomegalovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationAdenovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationEpstein Barr Virus reactivation or infection following allogeneic blood or marrow stem cell transplantation
Western Sydney Local Health District31 enrolled3 locationsACTRN12618000343202
Not Yet Recruiting
Phase 1
A phase 1 multicentre open label dose-escalation study of unrelated, major histocompatibility (MHC)-unmatched mesenchymals stem cells (MSC) for the treatment of steroid refractory acute graft versus host disease in recipients of allogeneic heamatopoietic stem cell transplants
Patients who have undergone a allogeneic stem cell transplant who have developed steroid refractory graft versus host disease
Mater Medical Research Institute9 enrolled1 locationACTRN12607000430437
Recruiting
Phase 1
Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT
Immune reconstitution post-allogeneic haematopoietic stem cell transplantation
Department of Haematology, Westmead Hospital12 enrolled1 locationACTRN12605000213640